Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

OncoVista Innovative Therapies Inc

Company price
None USD 0.00(0%)
Last update at 2025-07-23T13:00:02.821969Z
Market Cap
0.01M

Momentum Score

…

OncoVista Innovative Therapies, Inc., a biopharmaceutical company, develops targeted anticancer therapies by utilizing tumor-associated biomarkers. The company's product candidates include Cordycepin (OVI-123), which is in Phase I/II clinical trials for the treatment of refractory TdT positive leukemias; and L-Nucleoside Conjugates (OVI-117) that is under pre-clinical development for the treatment of colon cancer. The company was founded in 2004 and is based in San Antonio, Texas.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
0.00
Low
0.00
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
-
Dividend Yield
2.16%
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
-
ROE
-
Net Debt
-
ROCE
51.29%
Diluted EPS TTM
-

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2014-12-31 2013-12-31 2012-12-31 2011-12-31 2010-12-31
Type yearly yearly yearly yearly yearly
Date 2014-12-31 2013-12-31 2012-12-31 2011-12-31 2010-12-31
Income before tax -2.54M -1.45M -1.63M -2.23M -
Net income -2.54M -1.45M -1.63M -2.03M 10.10M
Selling general administrative 1.88M 0.62M 0.88M 1.04M 2.39M
Gross profit 0.00M 0.00M 0.00M 0.00M -
Ebit -2.55M -1.52M -1.98M -2.20M -
Operating income -2.55M -1.52M -1.98M -2.20M -
Interest expense 0.00M 0.00M 0.00M 0.00M 0.00M
Income tax expense 0.00M 0.00M 0.00M 0.00M -
Total revenue 0.00M 0.00M 0.00M 0.00M -
Total operating expenses 2.55M 1.52M 1.98M 2.20M -
Cost of revenue 0.00M 0.00M 0.00M 0.00M -
Total other income expense net 0.00M 0.07M 0.35M -0.03M -
Discontinued operations - - - 0.20M -
Net income from continuing ops -2.54M -1.45M -1.63M -2.23M -
Net income applicable to common shares -2.54M -1.45M -1.63M -2.03M -
Breakdown 2014-12-31 2013-12-31 2012-12-31 2011-12-31 2010-12-31
Type yearly yearly yearly yearly yearly
Date 2014-12-31 2013-12-31 2012-12-31 2011-12-31 2010-12-31
Total assets 0.01M 0.10M 0.58M 2.19M 3.55M
Other current assets - 0.05M 0.06M 0.05M -
Total liab 5.68M 3.22M 2.25M 2.31M 1.89M
Total stockholder equity -5.66M -3.12M -1.68M -0.12M 1.66M
Other current liab 0.45M 0.01M 0.09M 0.32M 1.29M
Common stock 0.02M 0.02M 0.02M 0.02M 0.02M
Retained earnings -25.90M -23.36M -21.91M -20.28M -
Other liab 0.70M - - - -
Other assets - - - - 0.00M
Cash 0.01M 0.04M 0.51M 2.13M 3.52M
Total current liabilities 4.98M 3.22M 2.25M 2.31M 1.89M
Short term debt 0.21M 0.01M 0.08M 0.17M -
Short long term debt 0.21M 0.01M 0.08M 0.17M -
Property plant equipment - 0.00M 0.00M 0.01M 0.02M
Total current assets 0.01M 0.10M 0.57M 2.18M -
Net tangible assets -5.66M -3.12M -1.68M -0.12M -
Accounts payable 1.67M 1.27M 0.93M 0.82M 0.51M
Breakdown 2014-12-31 2013-12-31 2012-12-31 2011-12-31 2010-12-31
Type yearly yearly yearly yearly yearly
Date 2014-12-31 2013-12-31 2012-12-31 2011-12-31 2010-12-31
Change to liabilities 0.41M 0.33M 0.12M 0.31M -
Total cashflows from investing activities - - - 0.20M 5.92M
Net borrowings 0.20M 0.20M -0.06M -0.06M -
Total cash from financing activities 0.20M 0.20M -0.06M 0.01M -
Change to operating activities 1.91M 0.71M 0.16M 0.04M -
Net income -2.54M -1.45M -1.63M -2.03M 10.10M
Change in cash -0.03M -0.47M -1.61M -1.40M -
Total cash from operating activities -0.23M -0.47M -1.55M -1.61M -
Depreciation 0.00M 0.00M 0.01M 0.01M -
Other cashflows from investing activities - - - 0.20M 5.92M
Change to account receivables - - - 0.01M 0.05M
Sale purchase of stock - - 0.00M 0.01M -
Change to netincome -0.01M -0.07M -0.21M 0.06M -
Capital expenditures 0.00M 0.00M 0.00M 0.00M 0.00M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
NVO
Novo Nordisk A/S
-1.05
2.58%
39.65 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc
3.46
0.65%
537.66 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc
-11.46
1.20%
946.29 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE
-
-%
965.00 45.77 31.25 13.84 7.12 36.06

Profile*

OncoVista Innovative Therapies Inc

OncoVista Innovative Therapies, Inc., a biopharmaceutical company, develops targeted anticancer therapies by utilizing tumor-associated biomarkers. The company's product candidates include Cordycepin (OVI-123), which is in Phase I/II clinical trials for the treatment of refractory TdT positive leukemias; and L-Nucleoside Conjugates (OVI-117) that is under pre-clinical development for the treatment of colon cancer. The company was founded in 2004 and is based in San Antonio, Texas.

14785 Omicron Drive, San Antonio, TX, United States, 78245

210-677-6000

2

Name Title Year Born
Dr. Alexander L. Weis Ph.D. Chairman, CEO, Pres, CFO, Principal Accounting Officer and Sec. 1950

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…